1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer

Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated...

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic...

Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial

Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates

Merck announces phase 3 waveLINE-010 trial initiation evaluating Zilovertamab Vedotin, an investigational antibody-drug conjugate, for...

Anti-HER2 bispecific ADC JSKN003 received approval to initiate a phase 3 clinical study for the...